Literature DB >> 7706458

Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases.

R R Reinhardt1, E Chin, J Zhou, M Taira, T Murata, V C Manganiello, C A Bondy.   

Abstract

Type III cGMP-inhibited phosphodiesterases (PDE3s) play important roles in hormonal regulation of lipolysis, platelet aggregation, myocardial contractility, and smooth muscle relaxation. We have recently characterized two PDE3 subtypes (PDE3A and PDE3B) as products of distinct but related genes. To elucidate their biological roles, in this study we compare cellular patterns of gene expression for these two enzymes during rat embryonic and postnatal development using in situ hybridization. PDE3B [corrected] mRNA is abundant in adipose tissue and is also expressed in hepatocytes throughout development. This mRNA is also highly abundant in embryonic neuroepithelium including the neural retina, but expression is greatly reduced in the mature nervous system. Finally, PDE3B [corrected] mRNA is localized in spermatocytes and renal collecting duct epithelium in adult rats. PDE3B mRNA is highly expressed in the cardiovascular system, including myocardium and arterial and venous smooth muscle, throughout development. It is also abundant in bronchial, genitourinary and gastrointestinal smooth muscle and epithelium, megakaryocytes, and oocytes. PDE3A [corrected] mRNA demonstrates a complex, developmentally regulated pattern of gene expression in the central nervous system. In summary, the two different PDE3s show distinctive tissue-specific patterns of gene expression suggesting that PDE3B [corrected] is involved in hormonal regulation of lipolysis and glycogenolysis, while regulation of myocardial and smooth muscle contractility appears to be a function of PDE3A [corrected]. In addition, the present findings suggest previously unsuspected roles for these enzymes in gametogenesis and neural development.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706458      PMCID: PMC295636          DOI: 10.1172/JCI117825

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  Insulin-sensitive phosphodiesterase. Its localization, hormonal stimulation, and oxidative stabilization.

Authors:  T Kono; F W Robinson; J A Sarver
Journal:  J Biol Chem       Date:  1975-10-10       Impact factor: 5.157

Review 2.  New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.

Authors:  W S Colucci; R F Wright; E Braunwald
Journal:  N Engl J Med       Date:  1986-02-06       Impact factor: 91.245

3.  Stimulation of a low Km phosphodiesterase from liver by insulin and glucagon.

Authors:  E G Loten; F D Assimacopoulos-Jeannet; J H Exton; C R Park
Journal:  J Biol Chem       Date:  1978-02-10       Impact factor: 5.157

4.  Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.

Authors:  S A Harrison; D H Reifsnyder; B Gallis; G G Cadd; J A Beavo
Journal:  Mol Pharmacol       Date:  1986-05       Impact factor: 4.436

5.  Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents.

Authors:  C H Macphee; S A Harrison; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

6.  A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.

Authors:  R Alvarez; G L Banerjee; J J Bruno; G L Jones; K Littschwager; A M Strosberg; M C Venuti
Journal:  Mol Pharmacol       Date:  1986-06       Impact factor: 4.436

7.  Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase.

Authors:  P G Grant; R W Colman
Journal:  Biochemistry       Date:  1984-04-10       Impact factor: 3.162

8.  Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique.

Authors:  P L Ludmer; R F Wright; J M Arnold; P Ganz; E Braunwald; W S Colucci
Journal:  Circulation       Date:  1986-01       Impact factor: 29.690

9.  An effect of insulin on adipose-tissue adenosine 3':5'-cyclic monophosphate phosphodiesterase.

Authors:  E G Loten; J G Sneyd
Journal:  Biochem J       Date:  1970-11       Impact factor: 3.857

10.  Two mutations in the dispensable part of alanine tRNA synthetase which affect the catalytic activity.

Authors:  M Jasin; L Regan; P Schimmel
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

View more
  22 in total

1.  Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes.

Authors:  Y H Choi; D Ekholm; J Krall; F Ahmad; E Degerman; V C Manganiello; M A Movsesian
Journal:  Biochem J       Date:  2001-01-01       Impact factor: 3.857

2.  Expression of type II cGMP-dependent protein kinase in rat kidney is regulated by dehydration and correlated with renin gene expression.

Authors:  S Gambaryan; C Häusler; T Markert; D Pöhler; T Jarchau; U Walter; W Haase; A Kurtz; S M Lohmann
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Phosphodiesterase 3 inhibitors suppress oocyte maturation and consequent pregnancy without affecting ovulation and cyclicity in rodents.

Authors:  A Wiersma; B Hirsch; A Tsafriri; R G Hanssen; M Van de Kant; H J Kloosterboer; M Conti; A J Hsueh
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

Review 4.  PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment.

Authors:  Shuichi Yanai; Shogo Endo
Journal:  Mol Neurobiol       Date:  2018-10-11       Impact factor: 5.590

5.  Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart.

Authors:  Sanja Beca; Faiyaz Ahmad; Weixing Shen; Jie Liu; Samy Makary; Nazari Polidovitch; Junhui Sun; Steven Hockman; Youn Wook Chung; Matthew Movsesian; Elizabeth Murphy; Vincent Manganiello; Peter H Backx
Journal:  Circ Res       Date:  2012-11-19       Impact factor: 17.367

Review 6.  Hormonal control of mammalian oocyte meiosis at diplotene stage.

Authors:  Meijia Zhang; Guoliang Xia
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

7.  Cilostazol strengthens barrier integrity in brain endothelial cells.

Authors:  Shoji Horai; Shinsuke Nakagawa; Kunihiko Tanaka; Yoichi Morofuji; Pierre-Oliver Couraud; Maria A Deli; Masaki Ozawa; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2012-12-07       Impact factor: 5.046

8.  Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility.

Authors:  Silvia Masciarelli; Kathleen Horner; Chengyu Liu; Sun Hee Park; Mary Hinckley; Steven Hockman; Taku Nedachi; Catherine Jin; Marco Conti; Vincent Manganiello
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 9.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 10.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.